Daratumumab, a human IgGκ monoclonal antibody that targets CD38, combined with lenalidomide and dexamethasone, reduces disease progression or mortality risk compared to lenalidomide and dexamethasone alone but has higher incidence of neutropenia and pneumonia 28. Here, CD38 is linked to pneumonia.